Education
About Us
Working with TipRanks
Follow Us
EKSO BIONICS (EKSO)
NASDAQ:EKSO
EKSO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.73 - $18.45
Previous CloseN/A
Volume1.71M
Average Volume (3M)46.94K
Market Cap
$11.49M
Enterprise Value$7.32M
Total Cash (Recent Filing)$5.24M
Total Debt (Recent Filing)$5.39M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Oct 30, 2025EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding2,611,788
10 Day Avg. Volume66,092
30 Day Avg. Volume46,942
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue0.50
Enterprise Value/Gross Profit0.97
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$6.75Price Target Upside44.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Product LaunchThe continued progress on the launch of the Indigo Personal product could provide a hedge to some of the macro challenges that the company is currently facing.
Sales GrowthProgress on distribution supports Indego Personal sales growth, with partners identifying at least 45 Medicare beneficiaries who are candidates for Indego Personal.
Bears Say
Customer Budget CutsSofter enterprise revenue due to customer budget cuts.
Order DelaysUnexpected order delays contributed to enterprise revenue softness during 2Q25.
Revenue DeclineEkso reported 2Q25 total revenues of $2.1M, a -58% YoY decline from $5.0M in 2Q24 and significantly below the consensus expectation of $4.3M.
EKSO BIONICS News
EKSO FAQ
What was EKSO BIONICS’s price range in the past 12 months?
EKSO BIONICS lowest stock price was $2.73 and its highest was $18.45 in the past 12 months.
What is EKSO BIONICS’s market cap?
EKSO BIONICS’s market cap is $11.49M.
When is EKSO BIONICS’s upcoming earnings report date?
EKSO BIONICS’s upcoming earnings report date is Oct 30, 2025 which is in 34 days.
How were EKSO BIONICS’s earnings last quarter?
EKSO BIONICS released its earnings results on Jul 28, 2025. The company reported -$1.24 earnings per share for the quarter, beating the consensus estimate of -$1.35 by $0.11.
Is EKSO BIONICS overvalued?
According to Wall Street analysts EKSO BIONICS’s price is currently Undervalued.
Does EKSO BIONICS pay dividends?
EKSO BIONICS does not currently pay dividends.
What is EKSO BIONICS’s EPS estimate?
EKSO BIONICS’s EPS estimate is -0.97.
How many shares outstanding does EKSO BIONICS have?
EKSO BIONICS has 2,611,788 shares outstanding.
What happened to EKSO BIONICS’s price movement after its last earnings report?
EKSO BIONICS reported an EPS of -$1.24 in its last earnings report, beating expectations of -$1.35. Following the earnings report the stock price went down -27.373%.
Which hedge fund is a major shareholder of EKSO BIONICS?
Currently, no hedge funds are holding shares in EKSO
Company Description
EKSO BIONICS
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
EKSO Company Deck
EKSO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.View all EKSO earnings summariesEKSO Stock 12 Month Forecast
Average Price Target
$6.75
▲(44.85% Upside)
Technical Analysis
Ownership Overview
6.10% Insiders
2.54% Mutual Funds
7.48% Other Institutional Investors
81.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---